Slay Sarcoma Research Initiative Request for Proposal (RFP)
Leiomyosarcoma Research

I. Background

Slay Sarcoma Research Initiative (SSRI) is offering two grant opportunities focusing on Leiomyosarcoma (LMS) research.

The mission of SSRI is to raise awareness and funding for leiomyosarcoma research. Projects funded by SSRI are the full responsibility of the recipient organization. SSRI has no influence over any aspect of the projects and only asks for reports about the results and the impact of the projects in order to share them publicly.

Leiomyosarcoma remains a difficult to treat disease despite the use of modalities such as chemotherapy and radiation. Knowledge gaps exist in areas concerning the etiology, progression and treatment of LMS. New biologic medications that target specific components of the immune system are recent discoveries that may prove to be useful in this disease. Combination of modalities may ultimately be needed in combating LMS, although specific agents, dosing and sequence of interventions need to be determined.

The intent of this document is to encourage research organizations to submit a letter of intent (LOI) in response to a Request for Proposal (RFP) that is related to basic or clinical LMS research focusing on etiology, progress and treatment of LMS. The RFP model is a two-stage process. Stage 1 is the submission of the LOI. After review of the LOI, you may be invited to submit your Full Grant Proposal. Stage 2 is the submission of the Full Grant Proposal.

II. Eligibility

Geographic Scope	United States Only
Applicant Eligibility Criteria	U.S. research institutions/organizations/association with a mission related to leiomyosarcoma research Collaborations within institutions (e.g. between departments) as well as between different institutions/organizations/associations, are encouraged. Please note all partners must have a relevant role and the requesting organization must have a key role in the project.

III. Requirements

Date RFP Issued	January 15, 2017
Clinical Area	Leiomyosarcoma
Expected Approximate Monetary Range of Grant Applications	Individual research projects requesting up to $20,000 will be considered. The total available budget related to this RFP is $40,000. The amount of the grant SSRI will be prepared to fund for any project will depend upon the internal review panel's evaluation of the proposal and costs involved and will be stated clearly in the approval notification

Key Dates	RFP release date: January 15, 2017 LOI due date: April 15, 2017. Please note the deadline is 11:59 pm Eastern Time, (New York, GMT -5) Review of LOIs by Internal Review Panel: April/May 2017 Full Proposal Deadline: June 1, 2017 *Only accepted LOIs will be invited to submit full proposals Please note deadline is midnight Eastern Time (New York, GMT -5) Review of Full Proposal by Internal Review Panel: June 2017 Anticipated distribution following execution of fully signed Letter of Agreement: July 2017 Period of Performance: August 1, 2017 to July 30, 2019.
How to Submit:	Email application to slaysarcoma@gmail.com
Questions	If you have questions regarding this RFP, please direct them in writing to the slaysarcoma@gmail.com
Mechanism by which Applicants will be Notified:	All applicants will be notified via email by the dates noted above. Applicants may be asked for additional clarification or to make a summary presentation during the review period.

IV. Terms and Conditions:

1. This RFP does not commit SSRI or its partners to award a grant or a grant of any particular size if one is awarded, nor to pay any costs incurred in the preparation of a response to this request.
2. SSRI reserves the right to accept or reject any or all applications received as a result of this request, or to cancel this RFP in part or in its entirety, if it determines it is in the best interest of SSRI to do so.
3. For compliance reasons and in fairness to all applicants, all communications about the RFP must come exclusively to SSRI at slaysarcoma@gmail.com.
4. Consistent with its commitment to openness and transparency, SSRI reports education grants provided to medical, scientific, and patient organizations in the United States. SSRI reserves the right to announce the details of successful grant application(s) by whatever means insures transparency, such as on the SSRI website, in presentations, and/or in other public media. In the case of this RFP, a list of all LOIs selected to move forward may be publicly disclosed. In addition, all approved full proposals, as well as all resulting materials (e.g., status updates, outcomes reports, etc.) may be posted on the SSRI website.
5. SSRI reserves the right to share with organizations that may be interested in contacting you for further information (e.g., possible collaborations) the title of your proposed project and the name, address, telephone number, and e-mail address of the applicant from the requesting organization.
6. To ensure compliance with applicable local law, SSRI may publicly disclose the support it provides. SSRI may disclose in any lawful manner the terms of the letter of agreement, the support or funding that SSRI is providing under the letter of agreement, and any other related information, to the extent necessary for SSRI to meet its obligations under those laws, regulations and industry codes that require SSRI to report payments or other transfers of value to certain healthcare professionals and teaching hospitals (collectively, the “Transparency Laws”). Transparency Laws include, without limitation, section 6002 of the U.S. Affordable Care Act and

the EFPIA Code on Disclosure of Transfers of Value. Disclosures may include identifying information for organizations and U.S. physicians, such as name, business address, specialty, National Provider Identifier (NPI), and licensure numbers. Grantee will agree to (and will cause other agents, employees and contractors to) reasonably cooperate with SSRI in SSRI's collection and disclosure of information to fulfill its Transparency Law obligations. Grantee will provide SSRI with complete and accurate information about payments or other transfers of value reportable under Transparency Laws.

7. No portion of an independent grant may be used for food and/or beverages for learners and/or participants in any capacity. Grantee will be required to certify during the reconciliation process and/or the periodic collection of grant reporting that funds were not used for food and/or beverages for learners and/or participants.
8. In the performance of all activities related to an independent grant, the Grantee and all participants must comply with all applicable Global Trade Control Laws. "Global Trade Control Laws" include, but are not limited to, U.S. Export Administration Regulations; the International Traffic in Arms Regulations; EU export controls on dual-use goods and technology; Financial Sanctions Laws and Restrictive Measures imposed within the framework of the CFSP - Treaty on European Union; and the economic sanctions rules and regulations administered by the U.S. Treasury Department's Office of Foreign Assets Control.
9. If grant is accepted and approved, documentation of IRB approval must be submitted for payment to be distributed.
10. For all Dissemination and Implementation research projects the institution(s) must agree to assume all responsibilities as sponsor of the study as outlined in the proposal, which includes:
    - Obtaining institutional review board (IRB)/independent ethics committee (IEC) approval for studies involving human subjects or human tissue and obtaining a subsequent renewal of this approval as required by local regulations (e.g., yearly, biannually, etc.). In addition, obtaining any IRB/IEC approval for amendments to protocol as they pertain to the research.
    - Obtaining all required personal data privacy or informed consent documentation (as appropriate).
    - Obtaining all required regulatory approval(s) per local regulations.
    - Assuming all reporting obligations to local regulatory authorities.
    - A statement that the research will be conducted in compliance with relevant provisions of the International Conference on Harmonisation, Good Clinical Practice, or Good Pharmacoepidemiology Practice guidelines and all applicable local legal and regulatory Requirements

Appendix: Letter of Intent Submission Guidance

LOIs should be single-spaced using Calibri 12-point font and 1-inch margins. There is a 3-page limit for the main section and a 1-page limit for organizational detail. If extensive, references may be included on 1 additional page. Final submissions should not exceed 5 pages in total (3 pages for the main section, 1 page for organizational detail, and 1 page for references).

LOIs should include the following sections:

- Main Section (not to exceed 3 pages):
  - A. Title
  - B. Background: It is expected that research projects follow generally accepted principals. For all research projects the institution(s) must agree to assume all responsibilities as sponsor of the study as outlined in the proposal.
    - At the time of approval of a full proposal, applicants will be required to sign a research contract, submit IRB approval and a research protocol.
  - C. Goals and Objectives
    Briefly state the overall goal of the project. Also describe how this goal aligns with the focus of the RFP and the goals of the applicant organization(s).
  - D. Assessment of Need for the Project
  - E. Project Design and Methods
  - F. Describe the planned project and the way it addresses the established need.
  - G. Evaluation and Outcomes
  - H. Anticipated Project Timeline
  - I. Requested Budget
    - A total amount requested is the only information needed for the LOI stage. Full Budget is not required. This amount can be adjusted at the Full Proposal stage as applicable.
    - The budget amount requested must be in U.S. dollars (USD).
    - While estimating your budget please keep the following items in mind:
      1. Institutional overhead and indirect costs may be included within the grant request. Examples include human resources department costs, payroll processing and accounting costs, janitorial services, utilities, property taxes, property and liability insurance, and building maintenance as well as additional project expenses such as costs for publication, IRB / IEC review fees, software license fees, and travel. Please note: SSRI does not provide funding for capital equipment.
      2. The inclusion of these costs cannot cause the amount requested to exceed the budget limit set forth in the RFP.
      3. SSRI maintains a maximum allowed overhead rate of 28% for independent research.
  - J. Additional Information:
    - If there is any additional information you feel SSRI should be aware of concerning the importance of this project, please summarize it in within the page limitations.

- Organizational Detail (not to exceed 1 page)
  - Describe the attributes of the institutions/organizations/associations that will support and facilitate the execution of the project and the leadership of the proposed project. Articulate the specific role of each partner in the proposed project. Letters of support from partner organizations will be required at the Full Proposal stage only and should not be included with the LOI.
  - Please note that any project partners listed in this section should also be listed within the online system. Tax-IDs of partner organizations will be requested when entering this

information. If a partnership is only proposed, please indicate the nature of the relationship in the Organizational Detail section of your LOI.

Please note the formatting and page limit for the LOI. The LOI is inclusive of additional information of any kind. A submission exceeding the page limit WILL BE REJECTED and RETURNED UNREVIEWED.